Clinical Trials Directory

Trials / Conditions / Clear Cell Renal Cell Carcinoma (ccRCC)

Clear Cell Renal Cell Carcinoma (ccRCC)

13 registered clinical trials studyying Clear Cell Renal Cell Carcinoma (ccRCC) — 9 currently recruiting.

StatusTrialSponsorPhase
RecruitingA Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advan
NCT07188896
Brian RiniPhase 2
Not Yet RecruitingCAIX PET/CT for Residual or Recurrent Post-ablative ccRCC
NCT07077083
Massachusetts General HospitalPhase 2
Not Yet RecruitingKSD-201 Treatment for Advanced Clear Cell Renal Cell Carcinoma: an Early Exploratory Clinical Study
NCT06708936
Kousai Bio Co., Ltd.EARLY_Phase 1
RecruitingPucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC
NCT07386158
Sun Yat-sen UniversityPhase 2
CompletedA Study to Evaluate the Safety and Dosimetry of 68Ga-OncoCAIX in Patients With CAIX-positive Cancer
NCT06840548
Philogen S.p.A.Phase 1
RecruitingMulticenter Study of 18F-Labeled NY104 for PET/CT Imaging in Renal Cell Carcinoma
NCT06916624
The Affiliated Hospital of Qingdao University—
RecruitingA First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemipl
NCT06413680
Regeneron PharmaceuticalsPhase 1 / Phase 2
CompletedEvaluation of HPGD and SCLO2A1 Expression in Clear Cell Renal Cell Carcinoma Patients
NCT06778538
Shang Panfeng—
RecruitingKO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
NCT06026410
Kura Oncology, Inc.Phase 1
RecruitingStudy of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
NCT05176483
ExelixisPhase 1
RecruitingA Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemipl
NCT03972657
Regeneron PharmaceuticalsPhase 1 / Phase 2
Active Not RecruitingA Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cel
NCT03634540
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Phase 2
TerminatedStudy CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC)
NCT02771626
Calithera Biosciences, IncPhase 1 / Phase 2